The abstract is read at the publisher; the summary is JClub's.
Male sex and concurrent NRTI or NNRTI resistance are linked to dolutegravir drug resistance in adults on DTG-based regimens across Malawi, Mozambique, Uganda, and Ukraine (2020–2022).
- Why it matters: Dolutegravir-based regimens dominate ART access, so identifying factors associated with resistance is critical to protect long-term efficacy where genotypic testing may be limited.
- What they did: Adults on DTG-based regimens with successful genotypes were analyzed using logistic regression; DTG resistance was defined by a Stanford genotypic susceptibility score > 15.
- The result: In multivariable models, male sex (OR 2.02, 95% CI 1.10–3.73), any NRTI resistance (OR 31.17, 95% CI 12.93–75.14), and any NNRTI resistance (OR 2.56, 95% CI 1.12–5.88) were associated with DTG resistance, and zidovudine-containing backbones remained linked (OR 5.87, 95% CI 2.45–14.07).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.